His scientific interests lie mostly in Tuberculosis, Mycobacterium tuberculosis, Isoniazid, Pharmacology and Pyrazinamide. His Tuberculosis study integrates concerns from other disciplines, such as Regimen, Internal medicine, Single-strand conformation polymorphism and Immunology. Jacques H. Grosset interconnects In vitro, Antibiotics, Microbiology, Virology and Virulence in the investigation of issues within Mycobacterium tuberculosis.
His Isoniazid study combines topics from a wide range of disciplines, such as Gastroenterology and Multiple drug resistance. His Pharmacology research integrates issues from Rifapentine, Pharmacotherapy and Rifamycin. The study incorporates disciplines such as Moxifloxacin, Chemotherapy and SQ109 in addition to Pyrazinamide.
His main research concerns Tuberculosis, Pharmacology, Mycobacterium tuberculosis, Microbiology and Antibacterial agent. His studies deal with areas such as Regimen, Internal medicine, Immunology and Clofazimine as well as Tuberculosis. His research in Pharmacology intersects with topics in Moxifloxacin and Rifapentine.
His Mycobacterium tuberculosis research incorporates themes from In vitro, Mutant, Gene, Lung and Granuloma. The Microbiology study combines topics in areas such as Guinea pig, Virology, In vivo and Ratón. His Antibacterial agent research includes themes of Clarithromycin and Rifampicin.
The scientist’s investigation covers issues in Tuberculosis, Pharmacology, Clofazimine, Rifapentine and Regimen. Jacques H. Grosset is interested in Mycobacterium tuberculosis, which is a field of Tuberculosis. His Pharmacology research is multidisciplinary, incorporating perspectives in Pyrazinamide, Ethambutol, Isoniazid and Bedaquiline.
His Ethambutol research includes elements of Culture conversion, Moxifloxacin and Clarithromycin. As a part of the same scientific family, Jacques H. Grosset mostly works in the field of Clofazimine, focusing on Dosing and, on occasion, Combination therapy and Guinea pig. His Rifapentine study incorporates themes from Rifamycin and TB chemotherapy.
His primary areas of investigation include Tuberculosis, Pharmacology, Clofazimine, Ethambutol and Mycobacterium tuberculosis. His research integrates issues of Gastroenterology and Regimen in his study of Tuberculosis. Regimen is closely attributed to Pyrazinamide in his study.
His Mycobacterium tuberculosis study combines topics in areas such as Complementation, Mutant, Efflux and Mutation. His work focuses on many connections between Culture conversion and other disciplines, such as Moxifloxacin, that overlap with his field of interest in Surgery. The various areas that Jacques H. Grosset examines in his Rifapentine study include Rifamycin and SQ109.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Vadim Makarov;Giulia Manina;Katarina Mikusova;Ute Möllmann.
Fluoroquinolones, tuberculosis, and resistance
Amy Sarah Ginsburg;Jacques H Grosset;William R Bishai.
Lancet Infectious Diseases (2003)
Nosocomial Bronchopneumonia in the Critically III: Histologic and Bacteriologic Aspects
J.-J. Rouby;E. Martin De Lassale;P. Poete;M.-H. Nicolas.
The American review of respiratory disease (1992)
A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis
Gyanu Lamichhane;Matteo Zignol;Natalie J. Blades;Deborah E. Geiman.
Proceedings of the National Academy of Sciences of the United States of America (2003)
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
Eric L. Nuermberger;Tetsuyuki Yoshimatsu;Sandeep Tyagi;Richard J. O'Brien.
American Journal of Respiratory and Critical Care Medicine (2004)
Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: A molecular study
B. Heym;N. Honoré;C. Schurra;S.T. Cole.
The Lancet (1994)
Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial.
Bertrand Dautzenberg;Chantal Truffot;Sophie Legris;Marie-Caroline Meyohas.
The American review of respiratory disease (1991)
Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans
S. Etuaful;B. Carbonnelle;J. Grosset;S. Lucas.
Antimicrobial Agents and Chemotherapy (2005)
Dormancy Phenotype Displayed by Extracellular Mycobacterium tuberculosis within Artificial Granulomas in Mice
Petros C. Karakousis;Tetsuyuki Yoshimatsu;Gyanu Lamichhane;Samuel C. Woolwine.
Journal of Experimental Medicine (2004)
Mycobacterium tuberculosis in the Extracellular Compartment: an Underestimated Adversary
Antimicrobial Agents and Chemotherapy (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: